Serum B2-M level and CD45dimCD38+CD138+CD56+CD19−CD117+CD27−CD81− BM myeloma PCs were selected as markers of tumor burden and were assessed in 48 and 38 treated MM patients, respectively. The gene discussed is B2M; the disease is Miyoshi myopathy.